Arsenical used in trypanosomiases. It may cause fatal encephalopathy and other undesirable side effects.
Agents destructive to the protozoal organisms belonging to the suborder TRYPANOSOMATINA.
A hemoflagellate subspecies of parasitic protozoa that causes Gambian or West African sleeping sickness in humans. The vector host is usually the tsetse fly (Glossina).
A disease endemic among people and animals in Central Africa. It is caused by various species of trypanosomes, particularly T. gambiense and T. rhodesiense. Its second host is the TSETSE FLY. Involvement of the central nervous system produces "African sleeping sickness." Nagana is a rapidly fatal trypanosomiasis of horses and other animals.
A republic in southern Africa, southwest of DEMOCRATIC REPUBLIC OF THE CONGO and west of ZAMBIA. Its capital is Luanda.
A nitrofuran thiazine that has been used against TRYPANOSOMIASIS.
Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of PNEUMOCYSTIS pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects.
A hemoflagellate subspecies of parasitic protozoa that causes Rhodesian sleeping sickness in humans. It is carried by Glossina pallidipes, G. morsitans and occasionally other species of game-attacking tsetse flies.
An inhibitor of ORNITHINE DECARBOXYLASE, the rate limiting enzyme of the polyamine biosynthetic pathway.
A republic in central Africa, east of the REPUBLIC OF THE CONGO, south of the CENTRAL AFRICAN REPUBLIC and north of ANGOLA and ZAMBIA. The capital is Kinshasa.
Inorganic or organic compounds that contain arsenic.
Disorders associated with acute or chronic exposure to compounds containing ARSENIC (ARSENICALS) which may be fatal. Acute oral ingestion is associated with gastrointestinal symptoms and an encephalopathy which may manifest as SEIZURES, mental status changes, and COMA. Chronic exposure is associated with mucosal irritation, desquamating rash, myalgias, peripheral neuropathy, and white transverse (Mees) lines in the fingernails. (Adams et al., Principles of Neurology, 6th ed, p1212)
An effective trypanocidal agent.
A subgroup of aquaporins that transport WATER; GLYCEROL; and other small solutes across CELL MEMBRANES.
Infection with protozoa of the genus TRYPANOSOMA.
Infections of the brain, spinal cord, or meninges by single celled organisms of the former subkingdom known as protozoa. The central nervous system may be the primary or secondary site of protozoal infection. These diseases may occur as OPPORTUNISTIC INFECTIONS or arise in immunocompetent hosts.
A republic in central Africa lying between GABON and DEMOCRATIC REPUBLIC OF THE CONGO and south of Cameroon. Its capital is Brazzaville.
Binary compounds of oxygen containing the anion O(2-). The anion combines with metals to form alkaline oxides and non-metals to form acidic oxides.
A hemoflagellate subspecies of parasitic protozoa that causes nagana in domestic and game animals in Africa. It apparently does not infect humans. It is transmitted by bites of tsetse flies (Glossina).
Measure of the number of the PARASITES present in a host organism.
A polyanionic compound with an unknown mechanism of action. It is used parenterally in the treatment of African trypanosomiasis and it has been used clinically with diethylcarbamazine to kill the adult Onchocerca. (From AMA Drug Evaluations Annual, 1992, p1643) It has also been shown to have potent antineoplastic properties.

Arsenic trioxide and melarsoprol induce apoptosis in plasma cell lines and in plasma cells from myeloma patients. (1/53)

Recent data have renewed the interest for arsenic-containing compounds as anticancer agents. In particular, arsenic trioxide (As2O3) has been demonstrated to be an effective drug in the treatment of acute promyelocytic leukemia by inducing programmed cell death in leukemic cells both in vitro and in vivo. This prompted us to study the in vitro effects of As2O3 and of another arsenical derivative, the organic compound melarsoprol, on human myeloma cells and on the plasma cell differentiation of normal B cells. At pharmacological concentrations (10(-8) to 10(-6) mol/L), As2O3 and melarsoprol caused a dose- and time-dependent inhibition of survival and growth in myeloma cell lines that was, in some, similar to that of acute promyelocytic leukemia cells. Both arsenical compounds induced plasma cell apoptosis, as assessed by 4',6-diamidino-2-phenylindole staining, detection of phosphatidylserine at the cell surface using annexin V, and by the terminal deoxynucleotidyl transferase-mediated nick end labeling assay. As2O3 and melarsoprol also inhibited viability and growth and induced apoptosis in plasma-cell enriched preparations from the bone marrow or blood of myeloma patients. In nonseparated bone marrow samples, both arsenical compounds triggered death in myeloma cells while sparing most myeloid cells, as demonstrated by double staining with annexin V and CD38 or CD15 antibodies. In primary myeloma cells as in cell lines, interleukin 6 did not prevent arsenic-induced cell death or growth inhibition, and no synergistic effect was observed with IFN-alpha. In contrast to As2O3, melarsoprol only slightly reduced the plasma cell differentiation of normal B cells induced by pokeweed mitogen. Both pokeweed mitogen-induced normal plasma cells and malignant plasma cells showed a normal nuclear distribution of PML protein, which was disrupted by As2O3 but not by melarsoprol, suggesting that the two arsenical derivatives acted by different mechanisms. These results point to the use of arsenical derivatives as investigational drugs in the treatment of multiple myeloma.  (+info)

Reversal of the sleep/wake cycle disorder of sleeping sickness after trypanosomicide treatment. (2/53)

To determine whether the circadian disruption of the sleep/wake cycle observed in sleeping sickness, human African trypanosomiasis (HAT), can be reversed after trypanosomicide treatment, 10 Congolese patients infected by Trypanosoma brucei gambiense underwent 24-h polysomnographic recordings before treatment with melarsoprol and after each of three weekly treatment sessions. Polysomnography consisted of a continuous recording of the electroencephalogram, electromyogram and electro-oculogram on a Minidix Alvar polygraph. Sleep traces were analysed in 20-sec epochs for wakefulness, REM sleep, and NREM sleep [stages 1, 2, 3, 4; stages 3 and 4 representing slow-wave sleep (SWS)]. As previously described (Buguet et al. 1993), the 24-h distribution of the sleep/wake cycle was disturbed proportionally to the severity of the illness. The overall amounts of each sleep/wake stage did not change after treatment. However, the patterns of occurrence of sleep episodes, REM sleep and SWS phases were determinant in the evaluation of treatment efficacy. The trypanosomicide action of melarsoprol led to a reduction in the number of sleep episodes, except in one patient whose health condition worsened during the third treatment session: sleep onset REM sleep phases (SOREMPs) decreased and the number of SWS episodes during a sleep episode increased. We conclude that in HAT, the reversibility of the sleep/wake cycle alteration and that of sleep structure constitute the basis for an evaluation of the healing process.  (+info)

Rhodesian trypanosomiasis in a splenectomized patient. (3/53)

We report the first apparent case of a splenectomized individual who developed severe trypanosomiasis with central nervous system involvement. The patient was a 41-year-old man who participated in an east African safari. Upon his return to the United States, the patient presented with an infection with Trypanosoma brucei rhodesiense that was treated successfully with suramin and melarsoprol. The onset of symptoms, laboratory studies, and disease progression did not differ from previously reported cases in the literature. The role of the spleen in trypanosomiasis is not well understood and the few reports available describe only animal models. This report suggests that asplenia had no apparent effect on the onset of symptoms and overall severity of illness. Further studies are necessary to ultimately define the role of the spleen in trypanosomiasis.  (+info)

Use of polymerase chain reaction in human African trypanosomiasis stage determination and follow-up. (4/53)

Stage determination of human African trypanosomiasis is based on the detection of parasites and measurements of biological changes in the cerebrospinal fluid (CSF) (concentration of white blood cells > 5 cells per mm3 and increased total protein levels). The patient is treated accordingly. Demonstration of the absence or presence of trypanosomes by the double centrifugation technique is still the only test available to clinicians for assessing treatment success. In this study, however, we evaluate the polymerase chain reaction (PCR) as a tool for assessing the disease stage of trypanosomiasis and for determining whether treatment has been successful. All 15 study patients considered to be in the advanced stage of the disease were PCR positive; however, trypanosomes were demonstrated by double centrifugation in only 11 patients. Of the five remaining patients, who were considered to be in the early stage, PCR and double centrifugation were negative. Following treatment, 13 of the 15 second-stage patients were found to be negative for the disease in at least two samples by PCR and double centrifugation. Two others were still positive by PCR immediately and one month after the treatment. Trypanosome DNA detection using PCR suggested that the two positive patients were not cured but that their possible relapse could not be identified by a search for parasites using the double centrifugation technique. Further evaluation of the PCR method is required, in particular to determine whether PCR assays could be used in studies on patients who fail to respond to melarsoprol, as observed in several foci.  (+info)

African trypanosomiasis in two travelers from the United States. (5/53)

African trypanosomiasis is a rare but well-documented cause of fever in United States travelers returning from areas where it is endemic. We report two recently diagnosed cases that involved tourists who went on safari in Tanzania. Review of these and 29 other published cases indicates that disease in returning United States travelers is nearly always of the East African form, a fulminant illness for which prompt diagnosis is necessary. In the United States, timely and appropriate therapy for this disease has resulted in favorable outcomes for most patients. Chemoprophylaxis for East African trypanosomiasis is not recommended, but travelers visiting areas of endemicity should practice appropriate preventive measures to prevent tsetse fly bites.  (+info)

Towards developing a diagnostic regimen for the treatment follow-up of Trypanosoma brucei gambiense. (6/53)

BALB/c mice infected with a high virulent strain of Trypanosoma brucei gambiense IL3707 were treated intraperitoneally (i.p.) with either Melarsoprol (Mel-B) or PSG(+) buffer as controls. The mice were subsequently monitored regularly for parasites by direct microscopic examination of their tail blood or buffy coat and by polymerase chain reaction (PCR). Mel-B was found to be an effective drug for treatment against T.b. gambiense because at the end of the first treatment schedule, all treated mice were negative for parasites even by PCR, while all the control animals were positive. Three of the five Mel-B treated mice, while parasitologically negative, were PCR positive between 53 and 80 days post infection (DPI), indicating that they still harbored an infection. All treated mice were subsequently negative for parasites even by PCR at 88 DPI. A combination of conventional microscopic examination and PCR offers a good prediction of cure following treatment of trypanosomosis.  (+info)

Novel therapeutic approach: organic arsenical melarsoprol) alone or with all-trans-retinoic acid markedly inhibit growth of human breast and prostate cancer cells in vitro and in vivo. (7/53)

The organic arsenical known as melarsoprol (Mel-B) is used to treat African trypanosomiasis. Recently, another arsenical, As2O3 was shown to be effective in treatment of acute promyelocytic leukaemia. We have investigated the anti-tumour activities of Mel-B either with or without all-trans-retinoic acid (ATRA) using the MCF-7 human breast cancer cells, as well as the PC-3 and DU 145 human prostate cancer cells both in vitro and in vivo. The antiproliferative effects of Mel-B and/or ATRA against breast and prostate cancer were tested in vitro using clonogenic assays and in vivo in triple immunodeficient mice. Furthermore, the mechanism of action of these compounds was studied by examining the cell cycle, levels of bcl-2, apoptosis and antiproliferative potency using a pulse-exposure assay. Clonogenic assays showed that the cancer cell lines were sensitive to the inhibitory effect of Mel-B (effective dose that inhibited 50% clonal growth [ED50]: 7 x 10(-9) M for MCF-7, 2 x 10(-7) M for PC-3, 3 x 10(-7) M for DU145 cells. Remarkably, the combination of Mel-B and ATRA had an enhanced antiproliferative activity against all three cancer cell lines. Furthermore, the combination of Mel-B and ATRA induced a high level of apoptosis in all three cell lines. Treatment of PC-3 and MCF-7 tumours growing in triple immunodeficient mice with Mel-B and ATRA either alone or in combination markedly retarded tumour size and weight of the tumours without major side-effects. In conclusion, our results suggest that either Mel-B alone or with ATRA may be a useful, novel therapy for breast and prostate cancers.  (+info)

Clinical description of encephalopathic syndromes and risk factors for their occurrence and outcome during melarsoprol treatment of human African trypanosomiasis. (8/53)

Encephalopathies are the most feared complications of sleeping sickness treatment with melarsoprol. To investigate the existence of risk factors, the incidence of encephalopathic syndromes and the relationship between the development of different types of encephalopathies and the clinical outcome was studied in a clinical trial with 588 patients under treatment with melarsoprol. The 38 encephalopathy cases were classified into three types according to the leading clinical picture: coma type, convulsion type and psychotic reactions. Nine patients were attributed to the convulsion type, defined as a transient event of short duration with convulsions followed by a post-ictal phase, without signs of a generalized disease. None of these patients died from the reaction. Febrile reactions in the 48 h preceding the reaction were generally not observed in this group. Twenty-five patients were attributed to the coma type, which is a progredient coma lasting several days. Those patients often had signs of a generalized disease such as fever (84%), headache (72%) or bullous skin (8%) reactions. The risk of mortality was high in this group (52%). About 14/16 patients with encephalopathic syndrome of the coma type were infected with malaria. Patients with psychotic reactions or abnormal psychiatric behaviour (3/38) and one patient who died after alcohol intake were excluded from the analysis. The overall rate of encephalopathic syndromes in the cases analysed (n=34) was 5.8%, of which 38.2% died. We did not find any parameters of predictive value for the risk of developing an encephalopathic syndrome based on the symptoms and signs before treatment initiation. The appearance during treatment of febrile reactions (RR 11.5), headache (RR 2.5), bullous eruptions (RR 4.5) and systolic hypotension (RR 2.6) were associated with an increased risk for the occurrence of encephalopathic syndromes especially of the coma type.  (+info)

Melarsoprol is an arsenic-based medication that is primarily used to treat the later stages of African trypanosomiasis, also known as sleeping sickness. It works by inhibiting the enzyme involved in energy metabolism of the parasite causing the disease, leading to its death. However, melarsoprol has a significant risk of serious side effects, including encephalopathy, which can be fatal. Therefore, it is typically used as a last resort when other treatments have failed or are not available. It is administered by intravenous injection in a hospital setting under close medical supervision.

Trypanocidal agents are a type of medication specifically used for the treatment and prevention of trypanosomiasis, which is a group of diseases caused by various species of protozoan parasites belonging to the genus Trypanosoma. These agents work by killing or inhibiting the growth of the parasites in the human body.

There are two main types of human trypanosomiasis: African trypanosomiasis, also known as sleeping sickness, which is caused by Trypanosoma brucei gambiense and Trypanosoma brucei rhodesiense; and American trypanosomiasis, also known as Chagas disease, which is caused by Trypanosoma cruzi.

Trypanocidal agents can be divided into two categories:

1. Drugs used to treat African trypanosomiasis: These include pentamidine, suramin, melarsoprol, and eflornithine. Pentamidine and suramin are used for the early stages of the disease, while melarsoprol and eflornithine are used for the later stages.
2. Drugs used to treat American trypanosomiasis: The main drug used for Chagas disease is benznidazole, which is effective in killing the parasites during the acute phase of the infection. Another drug, nifurtimox, can also be used, although it has more side effects than benznidazole.

It's important to note that trypanocidal agents have limited availability and are often associated with significant toxicity, making their use challenging in some settings. Therefore, prevention measures such as avoiding insect vectors and using vector control methods remain crucial in controlling the spread of these diseases.

Trypanosoma brucei gambiense is a species of protozoan flagellate parasite that causes Human African Trypanosomiasis, also known as sleeping sickness. It is transmitted to humans through the bite of an infected tsetse fly (Glossina spp.). The parasite multiplies in various body fluids, including blood and cerebrospinal fluid, leading to a range of symptoms such as fever, headache, joint pain, and eventually severe neurological disorders if left untreated. T. b. gambiense is responsible for the majority of reported cases in West and Central Africa and is considered to be an anthroponosis, meaning it primarily infects humans.

African trypanosomiasis, also known as sleeping sickness, is a vector-borne parasitic disease caused by the protozoan Trypanosoma brucei. It is transmitted to humans through the bite of an infected tsetse fly (Glossina spp.). The disease has two stages: an early hemolymphatic stage characterized by fever, swollen lymph nodes, and skin rashes; and a late neurological stage characterized by sleep disturbances, personality changes, and motor abnormalities. If left untreated, it can be fatal. The disease is endemic in sub-Saharan Africa, where an estimated 65 million people are at risk of infection.

I'm not aware of any medical definitions associated with the term "Angola." Angola is a country located in Southern Africa, known officially as the Republic of Angola. It does not have any specific relevance to medical terminology or healthcare. If you have more context or information about why you are looking for a medical definition of Angola, I may be able to provide a more helpful response.

Nifurtimox is an antiprotozoal medication used in the treatment of acute and chronic stages of American trypanosomiasis (Chagas disease) caused by Trypanosoma cruzi. It works by inhibiting the parasite's energy metabolism, ultimately leading to its death. Nifurtimox is often given orally in the form of tablets and its use is typically accompanied by close medical supervision due to potential side effects such as anorexia, nausea, vomiting, and neurological symptoms.

Pentamidine is an antimicrobial drug that is primarily used to treat and prevent certain types of pneumonia caused by the parasitic organisms Pneumocystis jirovecii (formerly known as P. carinii) and Leishmania donovani. It can also be used for the treatment of some fungal infections caused by Histoplasma capsulatum and Cryptococcus neoformans.

Pentamidine works by interfering with the DNA replication and protein synthesis of these microorganisms, which ultimately leads to their death. It is available as an injection or inhaled powder for medical use. Common side effects of pentamidine include nausea, vomiting, diarrhea, abdominal pain, and changes in blood sugar levels. More serious side effects can include kidney damage, hearing loss, and heart rhythm disturbances.

It is important to note that the use of pentamidine should be under the supervision of a healthcare professional due to its potential for serious side effects and drug interactions.

Trypanosoma brucei rhodesiense is a species of protozoan parasite that causes African trypanosomiasis, also known as sleeping sickness, in humans. It is transmitted through the bite of an infected tsetse fly and is endemic to certain regions of East and Southern Africa.

The life cycle of T. b. rhodesiense involves two hosts: the tsetse fly and a mammalian host (such as a human). In the tsetse fly, the parasite undergoes development and multiplication in the midgut, then migrates to the salivary glands where it transforms into the metacyclic trypomastigote stage. When the infected tsetse fly bites a mammalian host, the metacyclic trypomastigotes are injected into the skin and enter the lymphatic system and bloodstream, where they multiply by binary fission as bloodstream trypomastigotes.

The symptoms of African trypanosomiasis caused by T. b. rhodesiense include fever, headache, joint pain, and itching, which may progress to more severe symptoms such as sleep disturbances, confusion, and neurological disorders if left untreated. The disease can be fatal if not diagnosed and treated promptly.

It is important to note that T. b. rhodesiense is distinct from another subspecies of Trypanosoma brucei called T. b. gambiense, which causes a different form of African trypanosomiasis that is endemic to West and Central Africa.

Eflornithine is a antiprotozoal medication, which is used to treat sleeping sickness (human African trypanosomiasis) caused by Trypanosoma brucei gambiense in adults and children. It works by inhibiting the enzyme ornithine decarboxylase, which is needed for the growth of the parasite. By doing so, it helps to control the infection and prevent further complications.

Eflornithine is also used as a topical cream to slow down excessive hair growth in women due to a condition called hirsutism. It works by interfering with the growth of hair follicles.

It's important to note that Eflornithine should be used under the supervision of a healthcare professional, and it may have side effects or interactions with other medications.

The Democratic Republic of the Congo (DRC) is a country located in Central Africa. It is named after the Congo River, which flows through the country. The DRC is the second-largest country in Africa by area and the eleventh-largest in the world. It is home to a diverse population of more than 80 million people, making it one of the most populous countries on the continent.

The DRC is a democratic republic, which means that it is a form of government in which the people have the power to choose their leaders through free and fair elections. The country has a presidential system of government, in which the president serves as both the head of state and the head of government. The current president of the DRC is Félix Tshisekedi, who took office in January 2019.

The DRC is a federal republic, meaning that it is divided into several provinces, each with its own elected government. The country has a total of 26 provinces, which are further divided into districts and sectors.

The DRC is a member of various international organizations, including the United Nations, the African Union, and the Southern African Development Community. It is also a party to several international treaties and agreements, such as the Convention on International Trade in Endangered Species of Wild Fauna and Flora (CITES) and the Paris Agreement on climate change.

The DRC has a mixed economy, with both private and public sectors playing important roles. The country is rich in natural resources, including minerals such as copper, diamonds, gold, and tin. It also has large areas of fertile land that are suitable for agriculture. However, the DRC faces significant challenges, including poverty, corruption, and conflict. Despite these challenges, the country has made progress in recent years in terms of economic growth and development.

Arsenicals are a group of chemicals that contain arsenic, a naturally occurring element that is toxic to humans and animals. Arsenic can combine with other elements such as chlorine, sulfur, or carbon to form various inorganic and organic compounds known as arsenicals. These compounds have been used in a variety of industrial and agricultural applications, including wood preservatives, pesticides, and herbicides.

Exposure to high levels of arsenic can cause serious health effects, including skin damage, circulatory problems, and increased risk of cancer. Long-term exposure to lower levels of arsenic can also lead to chronic health issues, such as neurological damage and diabetes. Therefore, the use of arsenicals is regulated in many countries to minimize human and environmental exposure.

Arsenic poisoning is a condition that occurs when a person ingests or comes into contact with a toxic amount of arsenic, a naturally occurring element found in the earth's crust. Arsenic has no smell or taste, making it difficult to detect in food, water, or air.

Acute arsenic poisoning can occur after a single large exposure to arsenic, while chronic arsenic poisoning occurs after repeated or long-term exposure to lower levels of arsenic. The symptoms of acute arsenic poisoning include vomiting, diarrhea, abdominal pain, and muscle cramps. In severe cases, it can lead to death due to heart failure or respiratory failure.

Chronic arsenic poisoning can cause a range of health problems, including skin changes such as pigmentation and hard patches on the palms and soles, weakness, peripheral neuropathy, and an increased risk of cancer, particularly skin, lung, bladder, and kidney cancer. It can also affect cognitive development in children.

Arsenic poisoning is treated by removing the source of exposure and providing supportive care to manage symptoms. Chelation therapy may be used to remove arsenic from the body in cases of severe acute poisoning or chronic poisoning with high levels of arsenic. Prevention measures include monitoring and reducing exposure to arsenic in food, water, and air, as well as proper handling and disposal of arsenic-containing products.

Diminazene is an antiparasitic drug, primarily used in veterinary medicine to treat and prevent infections caused by trypanosomes, which are protozoan parasites that can affect both animals and humans. The drug works by inhibiting the protein synthesis of the parasite, leading to its death.

In human medicine, diminazene is used as an alternative treatment for acute African trypanosomiasis (sleeping sickness) caused by Trypanosoma brucei gambiense in areas where other treatments are not available or have failed. It is usually given by intramuscular injection and is often used in combination with suramin.

It's important to note that the use of diminazene in human medicine is limited due to its potential toxicity, and it should only be administered under the supervision of a healthcare professional.

Aquaglyceroporins are a subfamily of aquaporin water channels that also transport glycerol and other small solutes across biological membranes. They play important roles in various physiological processes, including osmoregulation, skin hydration, and fat metabolism. In humans, there are three known aquaglyceroporins: AQP3, AQP7, and AQP9.

Trypanosomiasis is a parasitic disease caused by various species of the protozoan genus Trypanosoma. It is transmitted through the bite of an infected tsetse fly (in African trypanosomiasis or sleeping sickness) or reduviid bug (in American trypanosomiasis or Chagas disease). The parasites enter the bloodstream and lymphatic system, causing symptoms such as fever, swollen lymph nodes, skin lesions, and muscle pain. Untreated, it can lead to severe neurological complications and death in both forms of the disease. Prevention measures include avoiding insect bites, using insect repellents, and sleeping under insecticide-treated bed nets.

Central nervous system (CNS) protozoal infections refer to diseases caused by protozoa that invade and infect the brain and spinal cord. These infections can lead to serious neurological symptoms and complications.

There are several types of protozoa that can cause CNS infections, including:

1. Toxoplasma gondii: This parasite is commonly found in cats and can be transmitted to humans through contact with infected cat feces or consumption of undercooked meat. In people with weakened immune systems, T. gondii can cause severe CNS symptoms such as seizures, confusion, and coma.
2. Naegleria fowleri: Also known as the "brain-eating amoeba," N. fowleri is a free-living protozoan found in warm freshwater environments. When people swim or dive in infected water, the amoeba can enter the body through the nose and travel to the brain, causing primary amoebic meningoencephalitis (PAM), a rare but often fatal CNS infection.
3. Acanthamoeba: Like N. fowleri, Acanthamoeba is a free-living protozoan found in freshwater and soil. It can cause a range of CNS infections, including granulomatous amoebic encephalitis (GAE), which typically affects people with weakened immune systems.
4. Trypanosoma brucei: This parasite is transmitted through the bite of infected tsetse flies and causes African sleeping sickness, a CNS infection that can lead to coma and death if left untreated.
5. Plasmodium falciparum: While not strictly a protozoan, P. falciparum is a parasite that causes malaria, a mosquito-borne disease that can cause severe CNS symptoms such as seizures, coma, and cerebral malaria.

Treatment for CNS protozoal infections depends on the specific type of infection and may include antiprotozoal medications, antibiotics, or supportive care to manage symptoms. Prevention measures include avoiding contact with infected animals or insects, practicing good hygiene, and using appropriate protective measures such as insect repellent or bed nets in areas where these infections are common.

I'm not aware of any medical definitions associated with the term "Congo." The term "Congo" is most commonly used to refer to:

1. The Congo River, which is the second longest river in Africa, flowing through the Democratic Republic of the Congo and the Republic of the Congo.
2. The two countries located in Central Africa that share the name "Congo": the Democratic Republic of the Congo (formerly known as Zaire) and the Republic of the Congo (formerly known as French Congo or Middle Congo).
3. In historical contexts, "Congo" may also refer to the Congo Free State (1885-1908), a private colony of King Leopold II of Belgium, which later became the Belgian Congo (1908-1960) and then Zaire (1971-1997).

If you are looking for medical information or definitions related to tropical diseases, healthcare in Africa, or similar topics, I would recommend using more specific terms.

I'm sorry for any confusion, but "oxides" is not a term that has a specific medical definition. Oxides are a class of chemical compounds that contain at least one oxygen atom and one other element. They can be formed through the process of oxidation, which involves the combination of oxygen with another substance.

In a broader sense, you might encounter the term "oxide" in a medical context when discussing various materials or substances used in medical devices, treatments, or research. For instance, titanium dioxide is a common ingredient in medical-grade sunscreens due to its ability to block and scatter UV light. However, it's important to note that the term "oxides" itself doesn't have a direct connection to medicine or human health.

Trypanosoma brucei brucei is a species of protozoan flagellate parasite that causes African trypanosomiasis, also known as sleeping sickness in humans and Nagana in animals. This parasite is transmitted through the bite of an infected tsetse fly (Glossina spp.). The life cycle of T. b. brucei involves two main stages: the insect-dwelling procyclic trypomastigote stage and the mammalian-dwelling bloodstream trypomastigote stage.

The distinguishing feature of T. b. brucei is its ability to change its surface coat, which helps it evade the host's immune system. This allows the parasite to establish a long-term infection in the mammalian host. However, T. b. brucei is not infectious to humans; instead, two other subspecies, Trypanosoma brucei gambiense and Trypanosoma brucei rhodesiense, are responsible for human African trypanosomiasis.

In summary, Trypanosoma brucei brucei is a non-human-infective subspecies of the parasite that causes African trypanosomiasis in animals and serves as an essential model organism for understanding the biology and pathogenesis of related human-infective trypanosomes.

Parasite load, in medical terms, refers to the total number or quantity of parasites (such as worms, protozoa, or other infectious agents) present in a host organism's body. It is often used to describe the severity of a parasitic infection and can be an important factor in determining the prognosis and treatment plan for the infected individual.

Parasite load can vary widely depending on the type of parasite, the route of infection, the immune status of the host, and other factors. In some cases, even a small number of parasites may cause significant harm if they are highly virulent or located in critical areas of the body. In other cases, large numbers of parasites may be necessary to produce noticeable symptoms.

Measuring parasite load can be challenging, as it often requires specialized laboratory techniques and equipment. However, accurate assessment of parasite load is important for both research and clinical purposes, as it can help researchers develop more effective treatments and allow healthcare providers to monitor the progression of an infection and evaluate the effectiveness of treatment.

Suramin is a medication that has been used for the treatment of African sleeping sickness, which is caused by trypanosomes. It works as a reverse-specific protein kinase CK inhibitor and also blocks the attachment of the parasite to the host cells. Suramin is not absorbed well from the gastrointestinal tract and is administered intravenously.

It should be noted that Suramin is an experimental treatment for other conditions such as cancer, neurodegenerative diseases, viral infections and autoimmune diseases, but it's still under investigation and has not been approved by FDA for those uses.

  • Before 2018, the treatment of HAT involved four drugs including pentamidine, suramin, melarsoprol and eflornithine, and more recently, a nifurtimox-eflornithine combination therapy (NECT). (biomedcentral.com)
  • In vitro assays were carried out in 96-well microtitre plates and melarsoprol and suramin were used as the positive controls. (ac.ke)
  • Melarsoprol and suramin at doses of 3.6 and 5 mk/kg bwt respectively were used as positive controls. (ac.ke)
  • The approval of the nifurtimox-eflornithine combination therapy (NECT) in 2009 for the treatment of T. b. gambiense limited the use of melarsoprol to the treatment of second-stage T. b. rhodesiense. (wikipedia.org)
  • In the meningoencephalitic or second stage, melarsoprol, an arsenic derivative, and eflornithine are the only effective drug treatments available ( 1 ). (cdc.gov)
  • Atouguia, J.M., Jennings, F.W. and Murray, M. (1995) Successful treatment of experimental murine Trypanosoma brucei infection with topical melarsoprol gel. (unl.pt)
  • Melarsoprol is an arsenic-containing medication used for the treatment of sleeping sickness (African trypanosomiasis). (wikipedia.org)
  • As a toxic organic compound of arsenic, melarsoprol is a dangerous treatment that is typically only administered by injection under the supervision of a licensed physician. (wikipedia.org)
  • It is used for patients in whom melarsoprol fails and is generally better tolerated and less toxic than arsenic drugs. (medscape.com)
  • 5. Arsenic trioxide and melarsoprol induce programmed cell death in myeloid leukemia cell lines and function in a PML and PML-RARalpha independent manner. (nih.gov)
  • 14. Comparative activity of melarsoprol and arsenic trioxide in chronic B-cell leukemia lines. (nih.gov)
  • citation needed] Melarsoprol used for the treatment of African trypanosomiasis with CNS involvement is given under a complicated dosing schedule. (wikipedia.org)
  • Studies have demonstrated the effectiveness of 10-day melarsoprol treatments for late-stage African trypanosomiasis. (medscape.com)
  • Each of these has their downsides - especially the toxic melarsoprol. (biomedcentral.com)
  • Dr. Wasunna noted that for decades the only treatment available for the disease was melarsoprol, a toxic treatment-said to cause "fire in the veins" - that killed one in 20 patients. (co.ke)
  • Unfortunately, melarsoprol-resistant parasites emerged as early as the 1970s and were widespread by the late 1990s. (nih.gov)
  • High relapse rates for patients treated with melarsoprol were documented in Uganda ( 2 , 3 ) and in M'banza Congo in Angola ( 4 ). (cdc.gov)
  • The relapse rate was calculated as the number of patients with HAT who experienced a relapse, divided by all patients who received full melarsoprol treatment during the study period. (cdc.gov)
  • Relapse after melarsoprol treatment was noted for 959 (19.5%) patients. (cdc.gov)
  • Table 2 shows characteristics of the patients with a relapse of HAT after melarsoprol treatment. (cdc.gov)
  • Melarsoprol is the drug of choice for late disease with central nervous system involvement (infections by T.b. gambiense or T. b. rhodiense ). (wikidoc.org)
  • This link between melarsoprol and AQP2 illustrates how a drug transporter can improve drug selectivity but, at the same time, highlights the risk of resistance when the drug uptake mechanism is dispensable for parasite viability and virulence. (nih.gov)
  • For these reasons, exclu- sion of ornithine decarhoxylase melarsoprol 4-p-(4.4-diamino-s-tria,in-3-yi-arnino) etlornithine is accompanied by advancing insulin resistance and were sought eagerly. (stonecottagegardens.com)
  • In regions of the world where the disease is common, melarsoprol is provided for free by the World Health Organization. (wikipedia.org)
  • Since melarsoprol is insoluble in water, dosage occurs via a 3.6% propylene glycol intravenous injection. (wikipedia.org)
  • The following are considerable treatment options: Melarsoprol is a treatment used during the second stage of the disease. (wikipedia.org)
  • Although melarsoprol cures about 96% of people with late stage disease, its toxicity limits its use. (wikipedia.org)
  • These data show that high failure rates with melarsoprol are no longer limited to Kasai Province in DRC. (cdc.gov)
  • Melarsoprol has a high number of side effects. (wikipedia.org)
  • Due to high toxicity, melarsoprol is reserved only for the most dangerous cases. (wikipedia.org)
  • One such metabolite, melarsen oxide, reaches maximum plasma levels about 15 minutes after melarsoprol injection. (wikipedia.org)
  • But one has to wait for the yearly reports of the "Organisation de Coordination contre les Endémies en Afrique Centrale" (OCEAC), between 1977 and 1997, to know that 146 sleeping sickness patients were diagnosed through a passive way in the Campo area. (moam.info)
  • Melarsoprol clearance is 21.5 ml/min/kg and the half-life of melarsen oxide is approximately 3.9 hours. (wikipedia.org)
  • Melarsoprol is water-insoluble and has a half-life of 35 hours. (medscape.com)

No images available that match "melarsoprol"